Hepatotoxicity during low-dose flutamide treatment for hirsutism

Gynecological Endocrinology

Volumn 25, Issue 7, 2009, Pages 419-422

  Castelo Branco, Camil ^a   Del Pino, Marta ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Adverse effects; Amenorrhea; Anti androgens; Flutamide; Hepatotoxicity; Hirsutism; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANDROGEN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DESOGESTREL; ESTRADIOL; FLUTAMIDE; FOLLITROPIN; GAMMA GLUTAMYLTRANSFERASE; LIPID; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN; SEX HORMONE BINDING GLOBULIN; SPIRONOLACTONE; TESTOSTERONE; TRIACYLGLYCEROL;

ACUTE HEPATITIS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMENORRHEA; ANDROGEN BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; BODY MASS; CASE REPORT; DISEASE DURATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG WITHDRAWAL; ECHOGRAPHY; FATTY LIVER; FEMALE; FOLLITROPIN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEALTH CARE ORGANIZATION; HIRSUTISM; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; JAUNDICE; KIDNEY FUNCTION TEST; LIPID BLOOD LEVEL; LIVER BIOPSY; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; LUTEINIZING HORMONE BLOOD LEVEL; NAUSEA; ORAL CONTRACEPTION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RATING SCALE; TESTOSTERONE BLOOD LEVEL; TRANSVAGINAL ECHOGRAPHY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANDROGEN ANTAGONISTS; DRUG-INDUCED LIVER INJURY; FEMALE; FLUTAMIDE; HIRSUTISM; HUMANS; HYPERANDROGENISM;

EID: 70350645081     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590902730754     Document Type: Article

References (33)

1. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007;370:685-697.
2. Rosenfield R. Hirsutism. N Engl J Med 2005;352:2578-2588.
3. Azziz R, Carmina E, Sawaya ME. Idiopathic hitsutism. Endocrinol Rev 2000;21:347-362.
4. Kirschner MA, Zucker IR, Jespersen D. Idiopathic hirsutism - an ovarian abnormality. N Engl J Med 1976;294:637-640.
5. Harwood K, Vuguin P, Dimartino-Nardi J. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Horm Res 2007;68:209-217.
6. Homburg R. Polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2008;22:261-274.
7. Bhathena RK. Therapeutic options in the polycystic ovary syndrome. J Obstet Gynaecol 2007;27:123-129.
8. Ibanez L, de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update 2006;12:243-252.
9. Moghetti P, Toscano V. Treatment of hirsutism and acne in hyperandrogenism. Best Pract Res Clin Endocrinol Metab 2006;20:221-234.
10. Castelo-Branco C, Martinez de Osaba MJ, Pons F, Fortuny A. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: Effects on hair, bone, and hormone profile after 1-year use. Metabolism 1997;46:437-440.
11. Castelo-Branco C, Martinez de Osaba MJ, Martinez S, Fortuny A. Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian- adrenal axis in women with severe hirsutism. Metabolism 1996;45:24-27.
12. Simard J, Luthy I, Guay J, Belanger A, Labrie F. Characteristic of interaction of the antiandrogen receptor in various target tissues. Mol Cell Endocrinol 1986;44:261-270.
13. Ayub M, Levell MJ.-Inhibition of rat testicular 17 alpha hydroxylase and 17, 20 lyase activities by antiandrogens. (flutamide, hydroxyflutamide, RU 23908, cyproterone acetate) in vitro. J Steroid Biochem 1987;28:43-47.
14. Brochu M, Belanger A, Dupont A, Cusan L, Labrie F. Effects of flutamide and aminoglutethimide on plasma 5 alpha reduced steroid glucronide concentrations in castrated patients with cancer of the prostate. J Steroid Biochem 1987;28:619-622.
15. Hatch R, Rosenfield R, Kim MH, Tredway D. Hirsutism: Implications, etiology, and management. Am J Obstet Gynecol 1981;140:815-826.
16. Goluboff ET, Hirano D, Thrasher JB, Stark G, Miller GJ, Glodé LM. New approaches to the treatment of prostatecancer. Rev Urol 2001;3:69-78.
17. Miquel M, Soler A, Vaqué A, Ojanguren I, Costa J, Planas R. Suspected cross-hepatotoxicity of flutamide and cyproterone acetate. Liver Int 2007;27:1144-1147.
18. Gomez JL, Dupont A, Cusan L, Tremblay M, Suburu R, Lemay M, Labrie F. Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med 1992;92:465-470.
19. Wysowski D, Freiman JP, Tourtelot JP, Horton ML III. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 1993;118:860-864.
20. Dikensoy E, Balat O, Pence S, Akcali C, Cicek H. The risk of hepatotoxicity during long-term and low-dose flutamide treatment in hirsutism. Arch Gynecol Obstet. 2009;279:321-327.
21. Calaf J, López E, Millet A, Alcañ iz J, FortunyA,Vidal O, Callejo J, Escobar-Jiménez F, Torres E, Espinó s JJ; Spanish Working Group for Hirsutism. Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: A 12-month, double-blind, parallel clinical trial. J Clin Endocrinol Metab 2007;92:3446-3452.
22. García Cortés M, Andrade RJ, Lucena MI, Sánchez Martínez H, Fernández MC, Ferrer T, Martín-Vivaldi R, Peláez G, Suárez F, Romero-Gómez M, et al. Flutamide induced hepatotoxicity: Report of a case series. Rev Esp Enferm Dig 2001;93:419-422.
23. Danan G, Benichou C. Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings: Application to druginduced liver injuries. J Clin Epidemiol 1993;46:1323-1330.
24. Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997;26:664-669.
25. Cusan L, Dupont A, Belanger A, Tremblay RR, Manhes G, Labrie F. Treatment of hirsutism with the pure antiandrogen flutamide. J Am Acad Dermatol 1990;23:462-469.
26. Gambineri A, Pelusa C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U, Pasquali R. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol 2004;60:241-249.
27. Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G, Duleba AJ. The effect of pure anti-androgen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2699-12270
28. Muderris II, Bayram F, Sahin Y, Keleştimur F. A comparison between two doses of flutamide (250 and 500 mg) in the treatment of hirsutism. Fertil Steril 1997;68:644-647.
29. Ibáñ ez L, Jaramillo A, Ferrer A, de Zegher F. Abscense of hepatotoxicity in hyperandrogenic girls and young women. Hum Reprod 2005;20:1833-1836.
30. Thole Z, Manso G, Salgueiro E, Revuelta P, Hidalgo A. Hepatotoxicity induced by antiandrogens: A review of the literature. Urol Int 2004;73:289-295.
31. Osculati A, Castiglioni C. Fatal liver complications with flutamide. Lancet 2006;367:1140-1141.
32. Fau D, Eugene D, Berson A, Letteron P, Fromenty B, Fisch C, Pessayre D. Toxicity of antiandrogen flutamide in isolate rat hepatocytes. J Pharmacol Exp Ther 1994;269:954-962.
33. Manolakopoulos S, Berthanis S, Armonis A, Economou M, Avgerinos A, Tzourmakliotis D. Toxic hepatitis after sequential administration of flutamide and cyproterone acetate. Dig Dis Sci 2004;49:462-465.